10月8日，Recursion Pharmaceuticals盘中下跌8.21%，报4.245美元/股，成交额1.2亿美元。
消息面上，公司与Tempus AI续签数据许可协议并新增RNA基础模型授权合作，但SEC文件显示Recursion被删除单方面终止协议的权利，同时原定两年最高8400万美元的酌情付款被替换为三年4200万美元的承诺付款，市场对合同刚性增强及短期现金流结构变化产生担忧。
行业方面，生物科技板块涨跌互现，Moderna上涨1.96%，艾伯维上涨2.53%，而Twist Bioscience下跌5.16%，板块内分化明显。
Recursion Pharmaceuticals是一家临床阶段的TechBio公司，通过其递归操作系统整合超过50PB的专有数据，在湿实验室实验与干实验室计算工具之间形成迭代循环，用于识别、验证和转化治疗洞见。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.